Form 4: BeOne Medicines SVP Sells Shares for Tax Withholding Upon RSU Vesting

BeOne Medicines Ltd.'s SVP and General Counsel, Chan Henry Lee, sold 422 American Depositary Shares on June 16, 2025, to cover mandatory tax withholding related to the vesting of restricted share units.

Summary

• Chan Henry Lee, the Senior Vice President and General Counsel of BeOne Medicines Ltd. (ONC), reported a transaction on June 16, 2025.
• The transaction involved the disposition of 422 American Depositary Shares (ADS) at a price of $266.5 per ADS.
• The sale was conducted to satisfy mandatory tax withholding obligations associated with the vesting of a previously granted restricted share unit (RSU) award.
• Each American Depositary Share represents 13 Ordinary Shares.
• The restricted share units are scheduled to vest at a rate of 1/4th on each anniversary of June 15, 2023, contingent upon continued service.
• Following this transaction, Chan Henry Lee directly beneficially owns 278,434 Ordinary Shares and 0 American Depositary Shares.

Sentiment

Score: 5

Explanation: The document reports a routine, non-discretionary sale of shares for tax withholding purposes, which is a neutral event for the company's operational performance or future prospects.

Positives

• The transaction is a routine, non-discretionary sale for tax withholding purposes, indicating a standard process for executive equity compensation rather than a lack of confidence in the company.

Negatives

• The sale of shares, while for tax purposes, represents a reduction in the insider's direct equity holdings in the company.

Risks

• No specific risks beyond general market and company-specific risks are detailed in this Form 4 filing, as it primarily reports an insider transaction.

Future Outlook

The remaining restricted share units held by the reporting person are subject to a vesting schedule where 1/4th of the securities will vest on each anniversary of June 15, 2023, provided continued service. Unvested securities are also subject to accelerated vesting upon certain termination events.

Management Comments

• "The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person."

Industry Context

This Form 4 filing details a routine insider transaction common across all industries, where executives sell a portion of their vested equity awards to cover tax liabilities. It does not provide specific insights into broader industry trends or competitive dynamics, as it is a compensation-related disclosure.

Comparison to Industry Standards

• The practice of selling shares to cover mandatory tax withholding upon the vesting of restricted share units is a standard and widely accepted procedure for executive compensation across publicly traded companies globally.
• This type of transaction is not indicative of a company's operational performance or strategic direction, but rather a compliance-driven event related to equity compensation plans.

Stakeholder Impact

• Shareholders: Minimal impact, as the sale is a routine tax-related transaction and not indicative of a change in company fundamentals or insider confidence.
• Employees: No direct impact on the broader employee base, as this relates to an individual executive's compensation.

Next Steps

• Continued vesting of the remaining restricted share units on subsequent anniversaries of June 15, 2023, subject to continued service.

Key Dates

Recommendation

Keywords

BeOne Medicines, ONC, SEC Form 4, Insider Transaction, Share Sale, Restricted Share Units, RSU Vesting, Tax Withholding, Executive Compensation, Chan Henry Lee